Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.61 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351048 | 0.76 | NQO2 (1.00) | NQO2TRPM4CYP1A2PTPN1ALOX5 | |
| SCHEMBL5147716 | 0.76 | NQO2 (1.00) | NQO2TRPM4CYP1A2PTPN1ALOX5 | |
| SCHEMBL6834828 | 0.76 | ALDH1A1 (0.44) | NQO2TRPM4CYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL28681 | 0.76 | NQO2 (1.00) | NQO2TRPM4CYP1A2PTPN1ALOX5 | |
| SCHEMBL8196720 | 0.76 | NQO2 (0.67) | NQO2TRPM4CYP1A2PTPN1ALOX5 | |
| Formaldehyde SCHEMBL27590428 | 0.76 | NQO2 (0.87) | NQO2TRPM4CYP1A2PTPN1ALOX5 | |
| SCHEMBL7838457 | 0.76 | PLAU (0.59) | NQO2CYP1A2PLAUIDO1KDM4E | |
| Naphthalene SCHEMBL25439100 | 0.74 | NQO2 (0.95) | NQO2TRPM4CYP1A2PTPN1ALOX5 | |
| SCHEMBL30260060 | 0.74 | NQO2 (0.64) | NQO2TRPM4CYP1A2PTPN1ALOX5 | |
| SCHEMBL4962010 | 0.74 | NQO2 (0.64) | NQO2TRPM4CYP1A2PTPN1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390246-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-12-07 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230105307-A1 | Identification of Stabilizers of Multimeric Proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-04-06 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| US-11337935-B2 | Identification of stabilizers of multimeric proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-05-24 | — | — | US | disclosed |
| EP-3935042-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | Conatus Pharmaceuticals, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| US-11136362-B2 | Peptide modulators of specific calcineurin protein-protein interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | Alhamadsheh, Mamoun M. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210277014-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | HISTOGEN, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-0890101-A1 | SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| WO-1998010778-A1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998011129-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INCORPORATED (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1997033174-A1 | SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-09-12 | — | — | WO | disclosed |
| CN-1157288-A | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105307-A1 | Identification of Stabilizers of Multimeric Proteins | TTR, HSPBP1, HSPH1 | NQO2 3501/4885TRPM4 1739/4885CYP1A2 4703/4885 |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | NQO2 2037/4885TRPM4 3670/4885CYP1A2 1018/4885 |
| US-20210277014-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | CASP1, CASP3, CASP6 | NQO2 3484/4885TRPM4 1183/4885CYP1A2 742/4885 |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | PTMS, QPCT, ANPEP | NQO2 2160/4885TRPM4 4101/4885CYP1A2 4228/4885 |
| US-11337935-B2 | Identification of stabilizers of multimeric proteins | TTR, HSPBP1, HSPH1 | NQO2 3501/4885TRPM4 1739/4885CYP1A2 4703/4885 |
| US-20230390246-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | TTR, PRNP, APP | NQO2 4007/4885TRPM4 4233/4885CYP1A2 3658/4885 |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | LENG8, TSG101, CD47 | NQO2 4066/4885TRPM4 4851/4885CYP1A2 3964/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | NQO2 2037/4885TRPM4 3670/4885CYP1A2 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.